ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears
Abivax SA (ABVX) shares fell 44% to a worst-ever day after late-stage ulcerative colitis trial results for obefazimod showed ~51% clinical remission at week 44 vs 10.4% on placebo, but reports of non-melanoma skin cancers and other malignancies in older patients raised safety concerns. Jefferies cut its target to $90 from $160 and downgraded to Hold; Wedbush raised to Neutral with $90 target. Martin Shkreli said GLP-1 fears later proved unfounded.
How this was made
The 30-second read
Why it matters
Obefazimod efficacy appears best-in-class, yet reported non-melanoma skin cancers and other malignancies create an FDA overhang. Analyst price targets were cut to $90 (Jefferies) and $90 (Wedbush), with Jefferies downgrading to Hold and Wedbush framing the risk as potentially leading to a black box warning.
Market read
Traders are likely to focus on whether the malignancy signal is adjudicated as drug-related and how it affects FDA review and potential label language, despite strong efficacy.
What to watch
The article does not quantify severity, adjudication, or dose-response beyond higher-dose arm; traders may be over-weighting headline cancer counts versus regulatory interpretation.
Background
The post references historical GLP-1 thyroid C-cell tumor fears (exenatide) to argue safety signals can resolve over time, but ABVX’s current catalyst is obefazimod late-stage ulcerative colitis data.
Ticker impact
Abivax shares fell 44% after late-stage obefazimod ulcerative colitis data showed 51% remission but reported non-melanoma skin cancers and other malignancies in older patients.
Near-term downside risk remains elevated as investors price in potential regulatory overhang (e.g., black box risk) despite positive efficacy.
The article cites a worst-day selloff, specific malignancy observations, and two analyst actions (Jefferies downgrade and Wedbush upgrade) both anchored to FDA risk framing.
Market effects
Reinforces that late-stage efficacy can be outweighed by malignancy safety signals, potentially tightening risk tolerance for GI immunology and oncology-adjacent biotech.
Limited, as the catalyst is company-specific and US-focused analyst actions are cited.
Moderate, as FDA label-risk concerns can affect broader investor sentiment toward similar trial safety profiles.
Counterpoint
The malignancies are described as rare and largely age-related, while the trial met multiple key secondary endpoints, suggesting the signal may not derail approval.
Key entities
- companyAbivax SA
Subject of the article, with obefazimod late-stage ulcerative colitis results and a sharp share selloff tied to malignancy safety signals.
- drug_candidateObefazimod
Abivax’s ulcerative colitis candidate whose trial showed 51% remission at week 44 but included reported malignancies in older patients.
- analyst_firmJefferies
Downgraded ABVX to Hold from Buy and cut the price target to $90 from $160.
- analyst_firmWedbush
Upgraded ABVX to Neutral from Underperform with a price target of $90.
- individualMartin Shkreli
Commented on the ABVX situation, arguing GLP-1 class fears historically resolved and that every trial is a roll of the dice.
